How World's Highest Bridge in China Compares to Golden Gate
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The Huajiang Canyon Bridge in China is set to open this month after three years of construction, becoming the highest bridge in the world.
The suspension bridge, which has been raised 2,051 feet above the canyon, will rise above the previous title holder, the Duge Bridge, which is 1,854 feet above the ground and is also in China.
The Context
Construction on the Huajiang Canyon Bridge began in 2022, in China's southwestern Guizhou region. It's scheduled to open this month after almost three years of work, despite the difficult mountain terrain in Guizhou. Once fully operational, the bridge will reduce the travel time across the canyon from more than an hour to just three minutes.
The Huajiang Grand Canyon Bridge under construction on November 27, 2024, in Qiandongnan Miao and Dong Autonomous Prefecture, Guizhou Province, China. On January 17, 2025, the bridge was connected across the canyon.
The Huajiang Grand Canyon Bridge under construction on November 27, 2024, in Qiandongnan Miao and Dong Autonomous Prefecture, Guizhou Province, China. On January 17, 2025, the bridge was connected across the canyon.
Tang Zhe/China News Service/VCG via AP
What To Know
At 2,051 feet above the canyon floor, the Huajiang Canyon Bridge is already one of the tallest structures in the world.
For comparison, the Golden Gate Bridge in California is just 220 feet above the water level, almost 10 times lower than its Chinese counterparts. Completed in 1937, the Golden Gtate Bridge is 746 feet high (including the towers), meaning it could fit under the Huajiang Canyon Bridge more than twice.
The highest suspension bridge in the U.S. is the Royal Gorge Bridge in Colorado, which was completed in 1929 and is suspended 956 feet above the Arkansas River.
The Huajiang Canyon Bridge has an official opening date of June 30, which means it was completed in less than three years, well ahead of schedule. Local Chinese media reported that builders worked on the structure throughout holidays to meet the deadline.
The Huajiang Canyon Bridge is a suspension bridge, which means it hangs the main deck from vertical suspenders at both ends. This design is best suited for very long main spans that need some leeway, as the design is relatively flexible.
Huajiang Canyon Bridge, set to be the world's tallest at 625m, spans 2,890m. A marvel of Chinese engineering, it's nearing completion for a 2025 opening.pic.twitter.com/YJPqoCvkFg — China Perspective (@China_Fact) May 29, 2025
What People Are Saying
Mamdouh El-Badry, a professor of civil engineering at the University of Calgary, told Newsweek:"In other parts of the world, a project of this scale would typically take five to 10 years from groundbreaking to completion, depending on environmental, political and logistical factors.
"Over the past 20 years, China has adopted a top-down approach to infrastructure, giving priority to large-scale projects to drive economic development and regional connectivity. This includes massive investment, fewer hurdles and streamlined approval processes compared to many Western countries which often face lengthy environmental reviews, funding uncertainties and local opposition, which can delay or often block major infrastructure efforts."
What Happens Next
The bridge will open properly for vehicle use on June 30. Chinese authorities hope it will help stimulate the Guizhou region's economy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
It's not just AI — China's quickly gaining an edge over the U.S. in biotech
BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China's rapid rise in biotechnology, especially for drug and agricultural development. Out of five critical tech sectors, "China has the most immediate opportunity to overtake the United States in biotechnology," the Harvard Belfer Center for Science and International Affairs said Thursday in its release of a "Critical and Emerging Technologies Index," covering AI, biotech, semiconductors, space and quantum. While the U.S. is still the leader in all five, "the narrow U.S.-China gap [in biotech] suggests that future developments could quickly shift the global balance of power," the report said. The assessment echoes growing concerns in Washington. In fact, the U.S. National Security Commission on Emerging Biotechnology struck a more urgent tone in an April report, citing two years of research. "There will be a ChatGPT moment for biotechnology, and if China gets there first, no matter how fast we run, we will never catch up," the bipartisan Congressional commission said in the report, referring to the transformative chatbot released by U.S.-based OpenAI. "Our window to act is closing. We need a two-track strategy: make America innovate faster, and slow China down," the commission said. It recommends that the U.S. government spend at least $15 billion over the next five years to support the domestic biotech sector. China's biotech industry has evolved to the point that U.S. and European pharmaceutical giants in the last several months have spent billions to acquire China-developed drugs that could treat cancer if commercialized with regulatory approval. In March, British pharmaceutical giant AstraZeneca announced it will invest $2.5 billion in a research and development center in Beijing. The Harvard Belfer Center pointed out that China's biotech strengths stem from its "dominance in pharmaceutical production and manufacturing," in addition to having more human talent than the U.S. China also has a "more flexible regulatory regime and the ability to push things out faster," Cynthia Y. Tong, one of the Harvard report's authors, told CNBC in an interview Thursday. She noted that the U.S. tends to have a longer approval process, as well as more drawn out research and development period. And just as China is developing its biotech sector, reports from the U.S. biotech hub of Cambridge and Boston are revealing layoffs and empty labs. China has long used multi-year plans and preferential state policies to encourage the development of key technologies. Biotech is no different, gaining high-level support back in 2007. "Currently, the U.S. government has no cohesive, intentional biotechnology strategy, while China is gaining ground thanks to its aggressive and carefully coordinated state-led initiatives," the U.S. security commission said. The worry is that just as Chinese restrictions on rare earths start to hit car manufacturers, Chinese dominance in biotech could become yet another form of leverage for Beijing over the U.S. and other countries. "The likelihood there's going to be cooperation [between the] U.S. and China on anything is very low, in some ways least likely on biotech and AI" because of the congressional report, said Eric Rosenbach, director of the defense, emerging technology, and strategy program at Harvard's Belfer Center. He was chief of staff at the U.S. Department of Defense from 2015 to 2017. He expects more U.S. pressure on China. It remains to be seen what that would mean in practice for businesses — though some say the future of biotech development is inherently global. Insilico Medicine, a startup using AI to cut drug discovery costs, relies on a global team spread across China, North America and the Middle East, according to its founder and CEO Alex Zhavoronkov. On Tuesday, the company announced with a paper in Nature Medicine that it was the first to see successful clinical testing with an AI-discovered drug. While Insilico's AI work typically happens in Canada and Abu Dhabi, the chemical testing and experiments are done in China, Zhavoronkov said, adding that the head of clinical development is in Boston. He declined to comment on a commercialization timeline in light of conversations with regulators. Other data shows that China has surpassed the U.S. in the number of clinical trials conducted, seen significant patent growth and boasts the most life sciences construction activity in the world. China-based Capital O venture partner Yang Fan, who previously worked in the pharmaceutical industry, said he expects the best biotech companies of the future will navigate different countries' regulations and use resources across the globe, if not benefit from arbitrage opportunities given different requirements and cost of entry in various markets. "The Chinese market is like a big supermarket for anything that can be commoditized, AI or biotechnology," he said, adding that new startups in China have to be "really good" to stand out. As AI drives innovation costs down, Fan predicts that in biotech, "the real DeepSeek moment is probably going to happen in five years."
Yahoo
8 hours ago
- Yahoo
Jamie Metzl and Steven Yates on China, national security threats
(NewsNation) — A Chinese scientist was arrested for allegedly trying to smuggle a dangerous fungus into the country. Author Jamie Metzl and Steven Yates with conservative think tank The Heritage Foundation say China is not taken as a serious threat by the U.S. and it should be. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
12 hours ago
- Yahoo
Toxic fungus smuggling case highlights safety issues facing research labs
Two Chinese scientists are accused of working together to smuggle a toxic fungus into the United States. Federal authorities say the researchers planned to study the samples in a lab at the University of Michigan, where one was employed. Scott MacFarlane has more.
